Atea Pharmaceuticals, Inc. (AVIR)

3.8500 +0.1500 (+4.05%) 收市：04:00PM EDT

Atea Pharmaceuticals, Inc.

225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 75

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Jean-Pierre Sommadossi Ph.D.	Founder, Chairman, CEO & President	1.04M	無	1956
Ms. Andrea J. Corcoran J.D.	CFO, Executive VP of Legal & Secretary	712.48k	無	1962
Mr. Keith Pietropaolo	Senior Vice President of Clinical Sciences	無	無	無
Dr. Jayanthi Wolf Ph.D.	Executive Vice President of Regulatory Affairs	無	無	無
Dr. Nancy Gail Berry Agrawal Ph.D.	Executive Vice President of Preclinical Development	無	無	無
Ms. Qi Huang	Senior Vice President of Virology	無	無	無
Ms. Kerry Gagnon	VP & Head of Quality	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

公司管治

截至 2024年4月29日 止，Atea Pharmaceuticals, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：3；董事會：10；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。